Ronald Goode, PhD

VP of Clinical Research and Scientific Affairs (retired) - Pfizer

Ronald L. Goode, Ph.D., President of The Goode Group, is a very successful executive (having been CEO of two public companies, President of International Operations of a major pharmaceutical company, etc.) with expertise in operations (full P&L responsibility; product development, launch and marketing; business development; mergers & acquisitions; financials and financing; etc.) on a global basis, whose experience (including serving as the only non-Japanese Director for a publicly held Japanese pharmaceutical company) on multiple Boards has gone beyond the usual governance problems to include helping develop successful strategies for defense against class action lawsuits, NASDAQ listing, etc. 

            Dr. Goode has held key management positions at Pfizer Pharmaceuticals (Vice President of Clinical Research and Scientific Affairs, Director of Marketing Research, etc) and at G. D. Searle & Co. (Senior Vice President of Commercial Development, President of Asia/Pacific World Area, President of Searle International).  He has an extensive record of success in business development, having been responsible for many of Searle's acquisitions, including DayProÒ, which became Searle's largest selling drug.  Dr. Goode has supervised clinical development programs that led to the filing of over a dozen New Drug Approval applications, including Pfizer's Procardia XLÒ and Searle's AmbienÒ. 

            Dr. Goode has served as President and Chief Executive Officer of two public companies:  Unimed Pharmaceuticals, Inc. and eXegenics Inc. (March 2001 - February, 2004).  He also served as a Director of Unimed from December 1997 until the company was sold to Solvay Et Cie, the Belgium-based conglomerate, in July of 1999.  He served on the Board of Directors of eXegenics from March, 2001 to December, 2003, the final year of which he also served as Chairman.  Other public companies that he has served as a Director include Vitro Diagnostics, Inc. (a Nevada company) and Hokuriku Seiyaku, a Japanese company.  He presently serves on the Board of Directors of Genitope (NASDAQ: "GTOP") and on the Advisory Boards of ART Recherchés et Technologies Avancées Inc. {a Canadian public (TORONTO: "ARA") medical devices company}, and Greystone Medical {a private company}.  He formed his own consulting company (dba "The Goode Group") for the purpose of advising Boards of Directors, CEOs, investment funds, and private individuals.  Under Sarbanes-Oxley, Dr. Goode is qualified to serve as an "Audit Committee Financial Expert".

            In 2000 Dr. Goode and his wife, Sheila, spent a sabbatical with his 'charity of choice', Mercy Ships International.  Among the non-profit Boards of Directors/Trustees on which he serves are Mercy Ships and Thunderbird, The Garvin Graduate School of International Management.  Dr. Goode received his Ph.D. in Microbial Genetics from the University of Georgia.